OR WAIT null SECS
November 09, 2015.
AstraZeneca has agreed to acquire ZS Pharma for $2.7 billion.
ZS Pharma’s leading product candidate is ZS-9, an investigational molecule for the treatment of high levels of potassium in the blood, or hyperkalemia. ZS-9 is believed to work by mimicking the function of physiological ion channels in cells.
Upon deal completion, AstraZeneca will wholly own ZS Pharma, which has approximately 200 employees. ZS Pharma’s board of directors has unanimously approved the terms of the agreement.